Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Osimertinib with Ramucirumab for EGFR-Mutated NSCLC
Randomized, open-label, multicenter, phase 2 study [RAMOSE trial] First-line metastatic EGFR-mutant NSCLC Osimertinib + Ramucirumab (n = 93) vs. Osimertinib alone (n = 46) unti
New Indication: Ibrutinib with Venetoclax for Mantle Cell Lymphoma
Randomised, double-blind, placebo-controlled phase 3 trial (SYMPATICO) Relapsed or refractory mantle cell lymphoma (MCL) after 1-5 prior therapies Ibrutinib 560 mg daily + Venetocl
New Indication: Enfortumab Vedotin for Head and Neck Cancer
Open-label, multicohort, phase II study (EV-202) Recurrent/metastatic head and neck cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors Enfortumab
New Protocol: Acalabrutinib + Venetoclax for Fixed Duration with/without Obinutuzumab
Phase 3, multicenter, open-label, randomized trial (AMPLIFY) Previously untreated CLL without del(17p) or TP53 mutation Acalabrutinib–venetoclax vs. acalabrutinib–venetoclax–
New Reference: Zenocutuzumab for NRG1 Fusion-Positive Cancer
Phase 2, open-label, multicenter clinical trial (eNRGy) Advanced/metastatic solid tumors with NRG1 fusion Zenocutuzumab 750 mg IV every 2 weeks
New Protocol: Ipilimumab + Nivolumab for MSI-H Colorectal Cancer
Phase 3, multicenter, open-label, randomized clinical trial (CheckMate 8HW) Unresectable or metastatic colorectal cancer with MSI-H/dMMR status, across all treatment lines Nivoluma
New Reference: Trastuzumab Emtansine in HER2-Positive Breast Cancer with Residual Disease
Phase 3, multicenter, randomized, controlled trial (KATHERINE) HER2-positive early breast cancer with residual invasive cancer after neoadjuvant therapy T-DM1 vs. trastuzumab (14 c
New Reference: Periop FLOT in Esophageal Cancer
Phase 3, multicenter, randomized, controlled trial (ESOPEC) Esophageal or GE junction adenoCa, cT1cN+, cT2–4a cN+, or cT2–4a cN0 FLOT (perioperative chemotherapy) vs. preoperat
New Drug: Datopotamab Deruxtecan for HR+, her2 Neg Breast Cancer
Phase 3, open-label, randomized study (TROPION-Breast01) Inoperable or metastatic HR+/HER2– breast cancer, previously treated with 1 or 2 lines of chemotherapy in the inoperable/
